A New Path Forward for Severe Alopecia Areata
Sun Pharmaceuticals has officially launched Leqselvi (deuruxolitinib)—an oral JAK1/JAK2 inhibitor—for adults with severe alopecia areata in the United States. The rollout follows the resolution of a patent dispute with Incyte, a legal roadblock that had delayed the drug’s entry into the U.S. market. Now, the 8 mg tablets are available by prescription nationwide.
Read more about this story on the Dermatology Times.
Leqselvi’s approval—granted by the FDA in July 2024—was backed by compelling results from phase 3 trials. In these studies, about one‑third of participants regained nearly full scalp hair by 24 weeks. A smaller group saw dramatic regrowth—80% or more scalp coverage—in just two months.
Analysts anticipate a strong U.S. market response. Projections estimate $400M to $900M in sales by fiscal year 2030, underlining both the clinical promise and commercial significance of the launch.
The availability of Leqselvi carries real meaning for patients. With limited treatment options for severe alopecia areata, this new prescription drug offers renewed hope for those struggling with autoimmune-related hair loss.
About Dr. Bruce Marko
Dr. Bruce Marko is a leading hair restoration surgeon with over 20 years of experience. As a plastic surgeon and FUE specialist, he is known for helping patients restore both their hair and confidence. Dr. Marko leads the team at RESTORE hair clinic, where he performs advanced, no-shave hair transplants designed to deliver natural-looking results with minimal downtime.
Leave a Reply